Can We Translate Non-inferiority Clinical Trial into Practice? Real World Outcome of Sunitinib and Pazopanib as First Line Targeted Therapy in Metastatic Renal Cell Carcinoma: UK Centre Experience

Purpose: Sunitinib and pazopanib are standards of care for the first line treatment of metastatic renal cell carcinoma (mRCC) across the world. A phase III clinical trial has shown that pazopanib is non-inferior to sunitinib as first line treatment for mRCC. However, it is likely that the comparative efficacy of these drugs may differ in real world clinical practice. We aim to evaluate the outcomes and compare toxicities of patients with mRCC treated with first line sunitinib or pazopanib in regular clinical practice.